Item 2.02 Results of Operations and Financial Condition.
On November 5, 2020, Prestige Consumer Healthcare Inc. (the "Company") announced
financial results for the fiscal quarter and six months ended September 30,
2020. A copy of the press release announcing the Company's earnings results for
the fiscal quarter and six months ended September 30, 2020 is attached hereto as
Exhibit 99.1 and incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
On November 5, 2020, representatives of the Company began making presentations
to investors regarding the Company's financial results for the quarter and six
months ended September 30, 2020 using slides attached to this Current Report on
Form 8-K as Exhibit 99.2 (the "Investor Presentation") and incorporated herein
by reference. The Company expects to use the Investor Presentation, in whole or
in part, and possibly with modifications, in connection with presentations to
investors, analysts and others during the fiscal year ended March 31, 2021.
By filing this Current Report on Form 8-K and furnishing the information
contained herein, the Company makes no admission as to the materiality of any
information in this report that is required to be disclosed solely by reason of
The information contained in the Investor Presentation is summary information
that is intended to be considered in the context of the Company's Securities and
Exchange Commission ("SEC") filings and other public announcements that the
Company may make, by press release or otherwise, from time to time. The Company
undertakes no duty or obligation to publicly update or revise the information
contained in this report, although it may do so from time to time as its
management believes is warranted. Any such updating may be made through the
filing of other reports or documents with the SEC, through press releases or
through other public disclosure.
The information presented in Items 2.02 and 7.01 of this Current Report on Form
8-K and Exhibits 99.1 and 99.2 shall not be deemed to be "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), or otherwise subject to the liabilities of that section, unless the
Company specifically states that the information is to be considered "filed"
under the Exchange Act or specifically incorporates it by reference into a
filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01 Financial Statements and Exhibits.
See Exhibit Index immediately following the signature page.
© Edgar Online, source Glimpses